EWING, NJ--(Marketwire - December 08, 2008) - DOR BioPharma, Inc. (OTCBB: DORB) (“DOR” or the “Company”), a late-stage biopharmaceutical company developing products to treat the life-threatening side effects of cancer treatments and serious gastrointestinal diseases, and vaccines against certain bioterrorism agents, announced today that the U.S. Food and Drug Administration (FDA) has completed its review and cleared the Investigational New Drug (IND) application for DOR201, a time-release formulation of oral beclomethasone dipropionate (oral BDP), for the prevention of acute radiation enteritis. DOR is, therefore, cleared to initiate a Phase 1/2 clinical trial in acute radiation enteritis.
